4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induces apoptosis in colon cancer partially through the induction of fas expression

In Vivo

Volumn 19, Issue 1, 2005, Pages 125-132

  Sako, Tatsuhiko ^a,c   Nakayama, Yoshifumi ^a   Minagawa, Noritaka ^a   Inoue, Yuzuru ^a   Onitsuka, Koji ^a   Katsuki, Takefumi ^a   Tsurudome, Yosuke ^a   Shibao, Kazunori ^a   Hirata, Keiji ^a   Nagata, Naoki ^a   Ohie, Shinji ^b   Kohno, Kimitoshi ^a   Itoh, Hideaki ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

^c KYUSHU ROSAI HOSPITAL   (Japan)

Author keywords

Apoptosis; Colon cancer; Fas; Hepatic metastasis; Rat model; TAC 101

Indexed keywords

4 [3,5 BIS(TRIMETHYLSILYL)BENZAMIDO]BENZOIC ACID; ANTINEOPLASTIC AGENT; BENZOIC ACID DERIVATIVE; FAS ANTIGEN; FAS LIGAND; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; SINGLE STRANDED DNA; TAC 101; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BINDING AFFINITY; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG RECEPTOR BINDING; EXPERIMENTAL NEOPLASM; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LAPAROTOMY; LIVER METASTASIS; METASTASIS INHIBITION; MITOSIS INHIBITION; NONHUMAN; RAT; TIME; WEIGHT REDUCTION;

EID: 20144389883     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Lippman, SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK, Holdener E and Krakoff IH: 13-Cis-retinoic acid plus interferon alpha 2a: a highly active systemic therapy for squamous cell carcinoma of cervix. J Natl Cancer Inst 84: 241-245, 1992.
2. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK, Holdener E and Krakoff IH: 13-Cis-retinoic acid plus interferon α2a: a locally advanced squamous cell carcinoma of cervix. J Natl Cancer Inst 85: 499-500, 1993.
3. Prevention of cancer in the next millennium. Report of chemoprevention working group to the American Association for Cancer Research. Cancer Res 59: 4743-4758, 1999.
4. Hong WK, Lippman SM, Hittelman WN and Lotan R: Retinoid chemoprevention of aerodigestive cancer: from basic research to the clinic. Clin Cancer Res 1: 677-686, 1995.
5. Hong WK and Sporn MB: Recent advances in chemoprevention of cancer. Science 278: 1073-1077, 1997.
6. Lippman SM, Kessler JF and Meyskens FL: Retinods as preventive and therapeutic anticancer agents (Part 1). Cancer Treat Rep 71: 391-405, 1987.
7. Jetten AM, Kim JS, Sacks PG, Rearick JI, Lotan D, Hong WK and Lotan R: Inhibition of growth and squamous cell differentiation markers in cultured human head and neck squamous carcinoma cells by beta-all-trans retinoic acid. Int J Cancer 45: 195-202, 1990.
8. Lotan R: Suppression of squamous cell carcinoma growth and differentiation by retinoids. Cancer Res 54: 1987-1990, 1994.
9. Lingen MW, Polverini PJ and Bouck NP: Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab Invest 74: 476-483, 1996.
10. Waghray A and Webber MM: Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells. Clin Cancer Res 1: 747-753, 1995.
11. Webber MM and Waghray A: Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid. Clin Cancer Res 1: 755-76, 1995.
12. Benbow U, Schoenermark MP, Orndorff KA, Givan AL and Brinckerhoff CE: Human breast cancer cells activate procollagenase-1 and invade type I collagen: invasion is inhibited by all-trans retinoic acid. Clin Exp Metastasis 17: 231-238, 1999.
13. Schoenermark MP, Mitchell TI, Rutter JL, Reczek PR and Brinckerhoff CE: Retinoid-mediated suppression of tumor invasion and matrix metalloproteinase synthesis. NY Acad Sci 878: 466-48, 1999.
14. Yamamoto H, Itoh F, Hinoda Y and Imai K: Suppression of matrilysin inhibits colon cancer cell invasion in vitro. Int J Cancer 61: 218-222, 1995.
15. Vermeulen SJ, Bruyneel EA, van Roy FM, Mareel MM and Bracke ME: Activation of E-cadherin/catenin complex in human MCF-7 breast cancer cells by all-trans-retinoic acid. Br J Cancer 72: 1447-145, 1995.
16. Murakami K, Wierzba K, Sano M, Shibata J, Yonekura K, Hashimoto A, Sano K and Yamada Y: TAC-101, a benzoic acid derivate, inhibits liver metastasis of human gastrointestinal cancer and prolongs the life-span. Clin Exp Metastasis 16: 323-331, 1998.
17. Murakami K, Matsuura T, Sano M, Hashimoto A, Yonekura K, Sakukawa R, Yamada Y and Saiki I: 4-[3,5-Bis(trimethylysilyl) benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals. Clin Exp Metastasis 16: 633-643, 1998.
18. Sakukawa R, Murakami K, Ikeda T, Yamada Y and Saiki I: Effect of 4-[3,5-Bis(trimethylysilyl) benzamido] benzoic acid (TAC-101) on the liver metastasis of Colon 26-L5 carcinoma cells. Oncol Res 10: 287-293, 1998.
19. Fujimoto K, Hosotani R, Doi R, Wada M, Lee J-U, Koshiba T, Miyamoto Y, Tsuji S, Nakajima S and Imamura M: Induction of cell-cycle arrest and apoptosis by a novel retinobenzoic-acid derivative, TAC-101, in human pancreatic cancer cells. Int J Cancer 81: 637-644, 1999.
20. Murakami K, Yamada T, Sudo K, Ohie S, Shibata J, Toko T, Yamada Y and Saiki I: TAC-101 (4-[3,5-Bis(trimethylysilyl) benzamido] benzoic acid) inhibits spontaneous mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma. Jpn J Cancer Res 90: 1254-1261, 1999.
21. Murakami K, Sakukawa R, Sano M, Hashimoto A, Shibata J, Yamada Y and Saiki I: Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101. Clin Cancer Res 5: 2304-2310, 1999.
22. Shibata J, Murakami K, Wierzba K, Aoyagi Y, Hashimoto A, Sano M, Toko T and Yamada Y: Anticancer effect of 4-[3,5-Bis(trimethylysilyl) benzamido] benzoic acid (TAC-101) against A549 non-small cell lung cancer cell line is related to its anti-invasive activity. Acticancer Res 20 3169-3176, 2000.
23. Shibata J, Murakami K, Aoyagi Y, Ohie S, Hashimoto A, Suzuki K, Sano M, Toko T, Wierzba K and Yamada Y: The induction of apoptosis and inhibition of AP-1 activity by TAC-101 (4-[3,5-Bis(trimethylysilyl) benzamido] benzoic acid) may result in life prolonging effect in animals bearing metastasizing cancer. Anticancer Res 20: 3583-3590, 2000.
24. Oikawa T, Murakami K, Sano M, Shibata J, Wierzba K and Yamada Y: A potential use of a synthetic retinoid TAC-101 as an orally active agent that blocks angiogenesis in liver metastases of human stomach cancer cells. Jpn J Cancer Res 92: 1225-1234, 2001.
25. Hashimoto Y, Kagechika H, Kawachi E, Fukasawa H, Saito G and Shudo K: Evaluation of differentiation-inducing activity of retinoids on human leukemia cell line HL-60 and NB4. Biol Pharm Bull 19: 1322-1328, 1996.
26. Inoue Y, Kashima Y, Aizawa K and Hatakeyama K: A new rat colon cancer cell line metastasized spontaneously: biologic characteristics and chemotherapeutic response. Jpn J Cancer Res 82: 90-97, 1991.
27. Okuno K, Hirai N, Lee YS, Kawai I, Shigeoka H and Yasutomi M: Involvement of liver-associated immunity in hepatic metastasis formation. J Surg Res 75: 148-152, 1998.
28. Watanabe I, Toyoda M, Okuda J, Tenjo T, Tanaka K, Yamamoto T, Kawasaki H, Sugiyama T, Kawarada Y and Tanigawa N: Detection of apoptotic cells in human colorectal cancer by two different in situ methods: antibody against single-stranded DNA and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) methods. Jpn J Cancer Res 90: 188-19, 1999.
29. Thompson CB: Apotosis in the pathogenesis and treatment of disease. Science 267: 1456-1462, 1995.
30. Hanabuchi S, Koyanagi M, Kawasaki A, Shinohara N, Matsuzawa A, Kobayashi Y, Yonehara S, Yagita H and Okumura K: Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad Sci USA 91: 4930-4934, 1994.
31. Sabattini E, Bisgaard K, Ascani S, Poggi S, Ceccarelli C, Pieri F, Fraternani-Orcioni G and Pileri A: The envision™+system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate™, CSA, LABC, and SABC techniques. J Clin Pathl 51: 506-51, 1998.
32. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ and Takahashi H: Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 94: 6420-6425, 1997.
33. Lee SW, Gleason N, Blanco I, Asi ZK and Whelan RL: Higher colon cancer tumor proliferative index and lower tumor cell death rate in mice undergoing laparotomy vs insufflation. Surg Endosc 16: 36-39, 2002.
34. Vermes I, Haanen C, Steffen-Nakken H and Reutelingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein-labeled annexin V. J Immunol Method 184: 39-51, 1995.
35. Bonneau MJ and Poulin R: Spermine oxidation leads to necrosis with plasma membrane phosphatidylserine redistribution in mouse leukemia cells. Exp Cell Res 259: 23-34, 2000.
36. Fisher GJ, Talwar HS, Lin J and Voorhees JJ: Molecular mechanisms of photoaging in human skin in vivo and their prevention by all-trans retinoic acid. Photochem Photobiol 69: 154-7, 1999.
37. Sato T, Koike L, Miyata Y, Hirata M, Mimaki Y, Sashida Y, Yano M and Ito A: Inhibition of activator protem-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 cells. Cancer Res 62: 1025-1029, 2002.
38. Finkenzeller G, Technau A and Marme D: Hypoxia-induced transcription of the vascular endothelial growth factor gene is independent of functional AP-1 transcription factor. Biochem Biophys Res Commun 208: 432-439, 1995.
39. Plaschke-Schlutter A, Behrens J, Gherardi E and Birchmeier W: Characterization of the scatter factor/hepatocyte growth factor gene promoter. J Biol Chem 270: 830-836, 1995.
40. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB, Karin M and Roberts AB: Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol 10: 1492-1497, 1990.
41. Miano JM, Topouzis S, Majesky MW and Olson EN: Retinoid receptor expression and all-trans retinoic acid-mediated growth inhibition in vascular smooth muscle cells. Circulation 93: 1886-1895, 1996.
42. Zhang LX, Mills KJ, Dawson M, Collins SJ and Jetten AM: Evidence for the involvement of retinoic acid receptor RAR alpha-dependent signaling pathway in the induction of tissue transglutaminase and apoptosis by retinoids. J Biol Chem 270: 6022-6029, 1995.
43. Horn V, Minucci S, Ogryzko VV, Adamson ED, Howard BH, Levin AA and Ozato K: RAR and RXR selective ligands cooperatively induce apoptosis and neuronal differentiation in P19 embryonal carcinoma cells. FASEB J 10: 1071-1077, 1996.
44. Lu XP, Fanjul A, Picard N, Pfahl M, Rungta D, Nared-Hood K, Carter B, Piedrafita J, Tang S, Fabbrizio E and Pfahl M: Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. Nat Med 3: 686-690, 1997.
45. Fanjul AN, Delia D, Pierotti MA, Rideout D, Yu JQ, Pfahl M and Qiu J: 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 271: 22441-22446, 1996.
46. Itoh N, Yonehara S, Ishii A, Yohenara M, Mizushima S, Sameshima M, Hase A, Seto Y and Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66 233-243, 1991.
47. Itoh N and Nagata S: A novel protein domain required for apoptosis. Mutation analysis of human Fas antigen. J Biol Chem 268: 10932-10937, 1993.
48. Möller P, Koretz K, Leithäuser F, Brüderlein S, Henne C, Quentmeier A and Krammer PH: Expression of APO-1 (CD95), member of NGF/TNF receptor surperfamily, in normal and neoplastic colon epithelium. Int J Cancer 57: 371-377, 1994.
49. Eberl LP, Guillou L, Saraga E, Schhröter M, French LE, Tschopp J and Juillerat-Jeanneret L: Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and rectal carcinomas. Int J Cancer 81: 772-778, 1999.
50. O'Connel J, O'Sullivan GC, Collins LK and Shanahan F: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184: 1075-1082, 1996.